WuXi STA's high potency drug product service covers both solid oral dosage and injectable formulation manufacturing. Our advanced GMP plants support up-to-commercial-scale drug product manufacturing. Combined with our upstream high potency API R&D and manufacturing capability in Changzhou and Jinshan sites located in geo proximity, WuXi STA provides integrated CMC services for high potency API and drug product from discovery to commercial manufacturing. 
WuXi STA has established high potency oral solid dosage manufacturing facilities in Shanghai Waigaoqiao site and Wuxi City site. Both sites support high potency oral drugs with formulation development services and drug product manufacturing services with our consistent global high standards.
Our high potency oral drug manufacturing features by state-of-the-art, fully enclosed production system with automated equipment. Its containment performance target (CPT) meets the control requirements of occupational exposure limit (OEL) as low as 10 ng/m3. We offer multiple formulation processes, including wet or dry granulation, tablet compression, and coating, as well as capsule filling, and can manufacture a variety form of tablets and capsules. Our annual production capacity is 400 million tablets and 200 million capsules.
The high potency sterile injectable manufacturing line is located at the drug product site in Wuxi City, China. Its occupational exposure limit (OEL) is 10 ng/m3. The fully enclosed isolation systems and automated filling machines minimize both microbial contamination and cross-contamination risks. The line has two 20m2 lyophilizers and supports liquid and lyophilized vials of various specifications. This line can efficiently perform the filling of up to 200 units per minute, achieving an annual capacity of over 12 million units. 
{{art.articleContent}}
{{art.subTitle}}
{{fa.cardTitle}}
{{fa.cardTitle}}
{{art.articleTitle}}
{{art.subTitle}}